大麻使用与精神分裂症风险的孟德尔随机化研究
该研究采用孟德尔随机化方法,以10个与大麻使用相关的独立遗传变异作为工具变量,在34 241例病例和45 604例对照中估计大麻使用对精神分裂症风险的因果效应。遗传学方法得出大麻使用者相比非使用者的精神分裂症OR为1.37(95%CI 1.09-1.67,P=0.007),观察性荟萃分析对应估计为1.43(95%CI 1.19-1.67),提示大麻使用与精神分裂症风险增加存在因果关联。
要点
- 遗传学工具变量分析支持大麻使用与精神分裂症风险增加存在因果关联。
- 大麻使用者精神分裂症风险OR为1.37(95%CI 1.09-1.67),与观察性估计1.43一致。
- 校正吸烟暴露后关联仍存在(OR 1.41,95%CI 1.09-1.83),遗传标记未见多效性证据。
核心结论
- 遗传学方法提示大麻使用与精神分裂症风险增加之间关系为因果性。
研究设计与样本
- 采用孟德尔随机化设计,使用10个先前在32 330名个体中识别的大麻使用相关独立遗传变异作为工具变量。
- 分析纳入34 241例病例和45 604例对照,主要来自欧洲血统人群。
- 将遗传学估计与报告曾使用大麻和精神分裂症或相关障碍风险的观察性研究荟萃分析进行比较。
主要发现
- 遗传学方法估计大麻使用者相比非使用者的精神分裂症OR为1.37(95%CI 1.09-1.67,P=0.007)。
- 观察性分析对应估计为1.43(95%CI 1.19-1.67,异质性P=0.76)。
- 遗传标记未显示多效性证据,校正吸烟暴露后关联未改变(OR 1.41,95%CI 1.09-1.83)。
关键数值与推荐
- 大麻使用者相比非使用者的精神分裂症遗传学估计OR为1.37(95%CI 1.09-1.67,P=0.007)。
- 观察性荟萃分析估计OR为1.43(95%CI 1.19-1.67,异质性P=0.76)。
- 校正吸烟暴露后OR为1.41(95%CI 1.09-1.83)。
临床怎么用
- 可为公共卫生信息提供依据,提示大麻使用潜在的精神健康后果。
局限性
- 原文未报告本研究的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cannabis use is observationally associated with an increased risk of schizophrenia, but whether the relationship is causal is not known. Using a genetic approach, we took 10 independent genetic variants previously identified to associate with cannabis use in 32 330 individuals to determine the nature of the association between cannabis use and risk of schizophrenia. Genetic variants were employed as instruments to recapitulate a randomized controlled trial involving two groups (cannabis users vs nonusers) to estimate the causal effect of cannabis use on risk of schizophrenia in 34 241 cases and 45 604 controls from predominantly European descent. Genetically-derived estimates were compared with a meta-analysis of observational studies reporting ever use of cannabis and risk of schizophrenia or related disorders. Based on the genetic approach, use of cannabis was associated with increased risk of schizophrenia (odds ratio (OR) of schizophrenia for users vs nonusers of cannabis: 1.37; 95% confidence interval (CI), 1.09-1.67; P-value=0.007). The corresponding estimate from observational analysis was 1.43 (95% CI, 1.19-1.67; P-value for heterogeneity =0.76). The genetic markers did not show evidence of pleiotropic effects and accounting for tobacco exposure did not alter the association (OR of schizophrenia for users vs nonusers of cannabis, adjusted for ever vs never smoker: 1.41; 95% CI, 1.09-1.83). This adds to the substantial evidence base that has previously identified cannabis use to associate with increased risk of schizophrenia, by suggesting that the relationship is causal. Such robust evidence may inform public health messages about cannabis use, especially regarding its potential mental health consequences.
引用
- Vaucher J, Keating BJ, Lasserre AM, et al. Cannabis use and risk of schizophrenia: a Mendelian randomization study. Mol Psychiatry. 2017. PMID: 28115737. doi:10.1038/mp.2016.252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。